

Literatura ACTA MEDICINAE 8–9/2022 Pneumoonkologie | Pneumologie

- 2 **Imunoterapie v léčbě pokročilého nemalobuněčného karcinomu plic**
MUDr. Helena Čoupková Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 2 **Léčba časných stadií nemalobuněčného karcinomu plic**
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha
- 2 **Léčba malobuněčného karcinomu plic**
MUDr. Bohdan Kadlec, Ph.D. Klinika nemocí plicních a tuberkulózy LF MU a FN Brno
- 3 **Léčba maligního mezoteliomu pleury**
MUDr. Petr Jakubec, Ph.D. | MUDr. Juraj Kultán | MUDr. Ondřej Fischer | MUDr. Andrea Müllerová
Klinika plicních nemocí a TBC FN a LF UP, Olomouc
- 4 **Program časného záchytu karcinomu plic**
MUDr. Ivana Čierná Peterová Ordinace Čierná-Peterová, Brandýs nad Labem-Stará Boleslav
- 4 **Diagnostika a terapie syndromu obstrukční spánkové apnoe**
doc. MUDr. Milan Sova, Ph.D. Klinika nemocí plicních a tuberkulózy, FN Brno, Klinika plicních nemocí a tuberkulózy, FN Olomouc
MUDr. Samuel Genzor, Ph.D. | MUDr. Jan Mizera Klinika plicních nemocí a tuberkulózy, FN Olomouc
- 4 **První jednoroční data z prospektivní observační studie postcovidových následků u kohorty pacientů z první vlny covidu-19 v Královéhradeckém kraji**
MUDr. Mikuláš Skála | MUDr. Michal Kopecký | MUDr. Libor Nevoránek Plicní klinika FN Hradec Králové, Lékařská fakulta Hradec Králové Univerzity Karlovy v Praze
Tereza Junková Lékařská fakulta Hradec Králové Univerzity Karlovy v Praze
doc. MUDr. Vladimír Koblížek, Ph.D. Plicní klinika FN Hradec Králové, Lékařská fakulta Hradec Králové Univerzity Karlovy v Praze
- 4 **Idiopatická plicní fibróza – farmakologické možnosti léčby**
MUDr. Martina Šterclová, Ph.D. Pneumologická klinika 2. LF UK a FN v Motole, Pneumologická klinika 1. LF UK a FTN, Praha
- 5 **Očkování pneumologických pacientů proti pneumokokům**
doc. MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha
- 5 **Vrozené poruchy imunitního systému manifestující se v dospělém věku**
MUDr. Zita Chovancová, Ph.D. Ústav klinické imunologie a alergologie FN u sv. Anny v Brně a LF Masarykovy univerzity, Brno
- 5 **Dlouhodobá léčba astmatu**
doc. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie 3. LF UK a Fakultní nemocnice Bulovka, vedoucí Národního centra pro těžké astma Fakultní nemocnice Bulovka, Praha
- 5 **Relvar Ellipta u pacienta s rozsáhlou medikací – kazuistika**
MUDr. Petra Adámková | doc. MUDr. Jaromír Bystron, CSc. Oddělení alergologie a klinické imunologie FN Ostrava a LF Ostravské univerzity, Ostrava
- 6 **Biologická léčba těžkého astmatu – současné možnosti a výhledy**
MUDr. Beáta Hutýrová, Ph.D. Oddělení alergologie a klinické imunologie, FN Olomouc, Ústav imunologie, LF UP, Olomouc
- 6 **Klinická účinnost kombinace budesonidu a formoterol fumarátu (Easyhaler) u nemocných se špatně kontrolovanou obstrukční nemocí dýchacích cest**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 6 **Fixní trojkombinace IKS/LAMA/LABA v inhalačním systému NEXThaler**
MUDr. Samuel Genzor, Ph.D. Klinika plicních nemocí a tuberkulózy FN a LF Univerzity Palackého, Olomouc
- 6 **Problematika indikace augmentační léčby deficitu α_1 -antitrypsinu**
MUDr. Jan Chlumský, Ph.D. | MUDr. Eva Bartošovská Národní centrum pro deficit α_1 -antitrypsinu, Pneumologická klinika, 1. LF UK a Fakultní Thomayerova nemocnice, Praha

Imunoterapie v léčbě pokročilého nemalobuněčného karcinomu plic

MUDr. Helena Čoupková Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- 1 ÚZIS, Novotvary 2017. Dostupné z: <https://www.uzis.cz/res/f/008352/novotvary2018.pdf>, vyhledáno 18. 5. 2022.
- 2 Cardenal, F. – Paz López-Cabrerizo, M. – Antón, A., et al.: Randomized phase III study of gemcitabine-cisplatin vs. etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. *J Clin Oncol*, 1999, 17, s. 1, 12–12.
- 3 Schiller, J. H. – Harrington, D. – Belani, Ch. P., et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med*, 2002, 346, s. 92–98.
- 4 Petruželka, L. – Špaček, J. – Křížová, L.: Budoucnost léčby karcinomu plic. *Klin Onkol*, 2021, 34, suppl. 1, s. S71–S81.
- 5 Pardoll, D. M.: The blockade of immune checkpoint proteins in cancer immunotherapy. *Nat Rev Cancer*, 2012, 12, s. 252–264.
- 6 Yervoy, SPC. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_cs.pdf, vyhledáno 18. 5. 2022.
- 7 Paz Ares, L. – Horn, L. – Borghaei, H.: Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non squamous cell (non SQ) non small cell lung cancer (NSCLC). *J Clin Oncol*, 2015, 33, suppl., abstrakt LBA109.
- 8 Borghaei, H. – Gettinger, S. – Vokes, E. E., et al.: Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. *J Clin Oncol*, 2021, 39, s. 723–733.
- 9 Fehrenbacher, L. – Spira, A. – Ballinger, M., et al.: POPLAR Study Group: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. *Lancet*, 2016, 387, s. 1837–1846.
- 10 Mazieres, J. – Rittmeyer, A. – Gadgeel, S., et al.: Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. *J Thorac Oncol*, 2021, 16, s. 140–150.
- 11 Reck, M. – Rodriguez-Abreu, D. – Robinson, A. G., et al.: KEYNOTE-024 Investigators: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med*, 2016, 375, s. 1823–1833.
- 12 Brahmer, J. R. – Rodriguez-Abreu, D. – Robinson, A. G.: KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥ 50%. *Ann Oncol*, 2020, 31, suppl. 4, s. S1142–S1215.
- 13 Herbst, R. S. – Giaccone, G. – de Marinis, F., et al.: Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. *N Engl J Med*, 2020, 383, s. 1328–1339.
- 14 Hellmann, M. D. – Paz-Ares, L. – Caro, R. B.: Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. *N Engl J Med*, 2019, 381, s. 2020–2031.
- 15 Paz-Ares, L. – Ciuleanu, T. E. – Lee, J. S.: Nivolumab + ipilimumab vs chemotherapy as first-line treatment for advanced non-small cell lung cancer: 4-year update from CheckMate 227 Oral presentation at the American Society for Clinical Oncology (ASCO) Annual Meeting; 4–8. 6. 2021, virtual, abstrakt 9016.
- 16 Paz-Ares, L. – Ciuleanu, T. E. – Cobo, M.: First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. *Lancet Oncol*, 2021, 22, s. 198–211.
- 17 Gandhi, L. – Rodriguez-Abreu, D. – Gadgeel, S., et al.: KEYNOTE-189 Investigators: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med*, 2018, 378, s. 2078–2092.
- 18 Gray, J. – Rodriguez-Abreu, D. – Powell, S. F.: Pembrolizumab + Pemetrexed-platinum vs pemetrexed-platinum for metastatic NSCLC: 4-year follow-up from KEYNOTE-189. *J Thorac Oncol*, 2021, 16, s. 224.
- 19 Paz-Ares, L. – Vicente, D. – Tafreshi, A., et al.: A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. *J Thorac Oncol*, 2020, 15, s. 1657–1669.
- 20 Robinson, A. G. – Baz, V. D. – Tafreshi, A., et al.: 970 – first-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407. *J Thorac Oncol*, 2021, 16, suppl. 4, s. S748–S802.
- 21 Socinski, M. A. – Nishio, M. – Jotte, R. M.: IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic non squamous NSCLC. *J Thorac Oncol*, 2021, 16, s. 1909–1924.
- 22 Antonia, S. J. – Villegas, A. – Daniel, D., et al.: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *N Engl J Med*, 2017, 377, s. 1919–1929.
- 23 Favre-Finn, C. – Baz, V. D. – Kurata, T.: Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC – an update from the PACIFIC trial. *J Thorac Oncol*, 2021, 16, s. 860–867.

Léčba časných stadií nemalobuněčného karcinomu plic

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha

- 1 Szeto, Ch. H. – Shalata, W. – Yakobson, A., et al.: Neoadjuvant and adjuvant immunotherapy in early-stage non-small-cell lung cancer, past, present, and future. *J Clin Med*, 2021, 10, s. 5614.
- 2 Bar, J. – Urban, D. – Ofek, E., et al.: Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase I study, MK3475-223. *J Clin Oncol*, 2019, 37, s. 8534–8534.
- 3 Gao, S. – Li, N. – Gao, S., et al.: Neoadjuvant PD-1 inhibitor (sintilimab) in NSCLC. *J Thorac Oncol*, 2020, 15, s. 816–826.
- 4 Lee, J. – Chaft, J. – Nicholas, A., et al.: P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIb NSCLC: Update on LCMC3 Clinical Trial. P780. Dostupné z: https://wclcl2019.iaslc.org/wp-content/uploads/2019/08/WCLC2019-Abstract-Book_web-friendly.pdf, vyhledáno 9. 6. 2022.
- 5 Spicer, J. – Wang, C. – Tanaka, F., et al.: Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2021, 39, suppl. 15, s. 8503–8503.
- 6 Heymach, J. – Taube, J. – Mitsudomi, T., et al.: P1.18-02 The AEGEAN phase 3 trial of neoadjuvant/adjuvant durvalumab in patients with resectable stage II/III NSCLC. *J Thorac Oncol*, 2019, 14, s. S625–S626.
- 7 Peters, S. – Spigel, D. – Ahn, M., et al.: P03.03 MERMAID-1: A phase III study of adjuvant durvalumab plus chemotherapy in resected NSCLC patients with MRD+ post-surgery. *J Thorac Oncol*, 2021, 16, s. S258–S259.
- 8 Spigel, D. R. – Peters, S. – Ahn, M. J., et al.: 93TIP MERMAID-2: phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy. *J Thorac Oncol*, 2021, 16, s. S745–S746.
- 9 Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671). ClinicalTrials.gov Identifier: NCT03425643.
- 10 A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) ClinicalTrials.gov Identifier: NCT03456063.
- 11 Cascone, T. – Provensio, M. – Sepesi, B., et al.: Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC. *J Clin Oncol*, 2020, 38, suppl. 15, DOI: 10.1200/JCO.2020.38.15_suppl.TPS9076.
- 12 Wakelee, H. A. – Altorki, N. K. – Zhou, C., et al.: IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIa non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2021, 39, suppl. 15, s. 8500–8500.
- 13 Paz-Ares, L. – O'Brien, M. E. R. – Mauer, M., et al.: VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study. *Ann Oncol*, 2022, dostupné z: <https://doi.org/10.1016/j.annonc.2022.02.224>, vyhledáno 9. 6. 2022.
- 14 Herbst, R. S. – Tsuboi, M. – John, T., et al.: Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIa EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. Presented at: ASCO20 Virtual Scientific Program. *J Clin Oncol*, 2020, 38, suppl., abstrakt LBAS.
- 15 Wu, Y.-L. – Tsuboi, M. – He, L., et al.: Osimertinib in resected EGFR-mutated non-small-cell lung cancer. *N Engl J Med*, 2020, 383, s. 1711–1723.
- 16 Chaft, J. E. – Dahlberg, S. E. – Khullar, O. V., et al.: EA5142 adjuvant nivolumab in resected lung cancers (ANVIL). *J Clin Oncol*, 2018, 36, suppl. 15, DOI: 10.1200/JCO.2018.36.15_suppl.TPS8581.
- 17 Double Blind Placebo Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC. ClinicalTrials.gov Identifier: NCT02273375.
- 18 Sands, J. M. – Mandrekar, S. J. – Kozono, D.: Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). *Immunotherapy*, 2021, 13, s. 727–734.

Léčba malobuněčného karcinomu plic

MUDr. Bohdan Kadlec, Ph.D. Klinika nemocí plicních a tuberkulózy LF MU a FN Brno

- 1 Krug, L. M. – Pietanza, M. C. – Kris, M. G., et al.: Small cell and other neuroendocrine tumors of the lung. In: DeVita, V.T. – Lawrence, T.S. – Rosenberg, S. A. (eds): *DeVita, Hellman and Rosenberg's Cancer, Principle and Practice of Oncology*. Wolters Kluwer; Lippincott Williams & Wilkins, Philadelphia, 2011, s. 848–870.
- 2 Kalemkerian, G. P. – Schneider, B. J.: Advances in small cell lung cancer. *Hematol Oncol Clin North Am*, 2017, 31, s. 143–156.
- 3 Govindan, R. – Page, N. – Morgensztern, D., et al.: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. *J Clin Oncol*, 2006, 24, s. 4539–4544.
- 4 Shepherd, F. A. – Lasky, J. – Evans, W. K., et al.: Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. *J Clin Oncol*, 1992, 10, s. 21–27.
- 5 Micke, P. – Faldum, A. – Metz, T., et al.: Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer – what limits limited disease? *Lung Cancer*, 2002, 37, s. 271–276.
- 6 Halvorsen, T. O. – Sundstrom, S. – Flotten, Ø., et al.: Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer. *Acta Oncol*, 2016, 55, s. 1349–1354.
- 7 Horn, L. – Mansfield, A. S. – Szczesna, A., et al.: First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. *N Engl J Med*, 2018, 379, s. 2220–2229.
- 8 Jiang, L. – Yang, K. H. – Guan, Q. L., et al.: Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials. *Intern Med J*, 2012, 42, s. 1297–1309.
- 9 Rossi, A. – Di Maio, M. – Chiodini, P., et al.: Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. *J Clin Oncol*, 2012, 30, s. 1692–1698.
- 10 Takada, M. – Fukuoka, M. – Kawahara, M., et al.: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. *J Clin Oncol*, 2002, 20, s. 3054–3060.
- 11 Schild, S. E. – Foster, N. R. – Meyers, J. P., et al.: Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis. *Ann Oncol*, 2012, 23, s. 2919–2924.
- 12 Paz-Ares, L. – Dvorkin, M. – Chen, Y., et al.: Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet*, 2019, 394, s. 1929–1939.
- 13 Natale, R. – Lara, P. – Chansky, K., et al.: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell

- lung cancer (E-SCLC). *J Clin Oncol*, 2008, 26, suppl., s. 400s.
- 14 Heigener, D. – Freitag, L. – Eschbach, C., et al.: Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease – small cell lung cancer (ED-SCLC): final results of a randomised phase III trial. *J Clin Oncol*, 2008, 26, suppl., s. 400s.
- 15 Zepzelca (lurbinectedin). Palo Alto, CA: Jazz Pharmaceuticals, Inc., červen 2020.
- 16 Anraku, M. – Waddell, T. K.: Surgery for small-cell lung cancer. *Semin Thorac Cardiovasc Surg*, 2006, 18, s. 211–216.
- 17 Cortinovis, D. – Bidoli, P. – Canova, S., et al.: Novel cytotoxic chemotherapies in small cell lung carcinoma. *Cancers*, 2021, 13, s. 1152.
- 18 Esposito, G. – Palumbo, G. – Carillio, G., et al.: Immunotherapy in small cell lung cancer. *Cancers*, 2020, 12, s. 2522.
- 19 Peifer, M. – Fernández-Cuesta, L. – Sos, M. L., et al.: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nat Genet*, 2012, 44, s. 1104–1110.
- 20 Alexandrov, L. B. – Nik-Zainal, S. – Wedge, D. C., et al.: Signatures of mutational processes in human cancer. *Nature*, 2013, 500, s. 415–421.

Léčba maligního mezoteliomu pleury

MUDr. Petr Jakubec, Ph.D. | MUDr. Juraj Kultán | MUDr. Ondřej Fischer | MUDr. Andrea Müllerová

Klinika plicních nemocí a TBC FN a LF UP, Olomouc

- 1 Testa, J. R., et al.: Germline BAP1 mutations predispose to malignant mesothelioma. *Nature Genetics*, 2011, 43, s. 1022–1025.
- 2 Yang, H. – Xu, D. – Schmid, R. A., et al.: Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma. *Ther Adv Med Oncol*, 2020, 12, 1758835920971421.
- 3 Lin, R. T. – Takahashi, K. – Karjalainen, A., et al.: Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. *Lancet*, 2007, 369, s. 844–8449.
- 4 Palatka, K. – Kolek, V. – Tichý, T., et al.: Zkušenosti s diagnostikou a léčbou maligního mezoteliomu, srovnání období 1990–1999 a 2000–2004. *Stud Pneumol Phthiseol*, 2007, 67, s. 188–193.
- 5 Herndon, J. E. – Green, M. R. – Chahinian, A. P., et al.: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. *Chest*, 1998, 113, s. 723–731.
- 6 Petersen, T. R. – Panou, V. – Meristoudis, C., et al.: Clinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting. *Acta Oncol*, 2021, 60, s. 521–527.
- 7 Flores, R. M. – Pass, H. I. – Seshan, V. E., et al.: Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. *J Thorac Cardiovasc Surg*, 2008, 135, s. 620–6, 626.e1–3.
- 8 Burt, B. M. – Cameron, R. B. – Mollberg, N. M., et al.: Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality. *J Thorac Cardiovasc Surg*, 2014, 148, s. 30–35.
- 9 Lauk, O. – Hoda, M. A. – de Perrot, M., et al.: Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions. *Ann Thorac Surg*, 2014, 98, s. 1748–1754.
- 10 Treasure, T. – Lang-Lazdunski, L. – Waller, D., et al.: MARS trialists: Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. *Lancet Oncol*, 2011, 12, s. 763–772.
- 11 Tsao, A. S. – Lindwasser, O. W. – Adjei, A. A., et al.: Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. *J Thorac Oncol*, 2018, 13, s. 1655–1667.
- 12 Waller, D. A. – Opitz, I. – Bueno, R., et al.: Divided by an ocean of water but united in an ocean of uncertainty: a transatlantic review of mesothelioma surgery guidelines. *Ann Thorac Surg*, 2021, 111, s. 386–389.
- 13 Gomez, D. R. – Rimmer, A. – Simone, C. B. 2nd., et al.: The use of radiation therapy for the treatment of malignant pleural mesothelioma: expert opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. *J Thorac Oncol*, 2019, 14, s. 1172–1183.
- 14 Shaikh, F. – Zauderer, M. G. – von Reibnitz, D., et al.: Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma. *J Thorac Oncol*, 2017, 12, s. 993–1000.
- 15 Krayenbuehl, J. – Oertel, S. – Davis, J. B., et al.: Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleurectomy/pneumonectomy. *Int J Radiat Oncol Biol Phys*, 2007, 69, s. 1593–1599.
- 16 Rimmer, A. – Spratt, D. E. – Zauderer, M. G., et al.: Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma. *Int J Radiat Oncol Biol Phys*, 2014, 90, s. 394–401.
- 17 Feigen, M. – Lee, S. T. – Lawford, C., et al.: Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation. *J Med Imaging Radiat Oncol*, 2011, 55, s. 320–332.
- 18 Kristensen, C. A. – Notttrup, T. J. – Berthelsen, A. K., et al.: Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. *Radiother Oncol*, 2009, 92, s. 96–99.
- 19 de Perrot, M. – Feld, R. – Leigh, N. B., et al.: Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. *J Thorac Cardiovasc Surg*, 2016, 151, s. 468–473.
- 20 Krug, L. M. – Pass, H. I. – Rusch, V. W., et al.: Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. *J Clin Oncol*, 2009, 27, s. 3007–3013.
- 21 Weder, W. – Stahel, R. A. – Bernhard, J., et al.; Swiss Group for Clinical Cancer Research: Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. *Ann Oncol*, 2007, 18, s. 1196–1202.
- 22 Sugarbaker, D. J. – Flores, R. M. – Jaklitsch, M. T., et al.: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. *J Thorac Cardiovasc Surg*, 1999, 117, s. 54–63.
- 23 Tillemann, T. R. – Richards, W. G. – Zellos, L., et al.: Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. *J Thorac Cardiovasc Surg*, 2009, 138, s. 405–411.
- 24 Szkorupa, M. – Klos, D. – Chudáček, J., et al.: Hypertermická peroperační intrapleurální chemoterapie a chirurgická cytoredukce jako součástí multimodální léčby maligního mezoteliomu pleury – kazistika. *Rozhl Chir*, 2020, 99, s. 456–461.
- 25 de Bree, E. – van Ruth, S. – Baas, P. R., et al.: Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. *Chest*, 2002, 121, s. 480–487.
- 26 van Ruth, S. – Baas, P. – Haas, R. L., et al.: Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. *Ann Surg Oncol*, 2003, 10, s. 176–82.
- 27 Ried, M. – Kovács, J. – Markowiak, T., et al.: Hyperthermic Intrathoracic Chemotherapy (HI-TOC) after cytoreductive surgery for pleural malignancies – a retrospective, multicentre study. *Cancers*, 2021, 13, s. 4580.
- 28 Migliore, M. – Calvo, D. – Criscione, A., et al.: Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: preliminary experience. *Future Oncol*, 2015, 11, suppl., s. 47–52.
- 29 Enewold, L. – Sharon, E. – Thomas, A.: Patterns of care and survival among patients with malignant mesothelioma in the United States. *Lung Cancer*, 2017, 112, s. 102–108.
- 30 Vogelzang, N. J. – Rusthoven, J. J. – Symanowski, J., et al.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol*, 2003, 21, s. 2636–2644.
- 31 Zalcman, G. – Mazieres, J. – Margery, J., et al.; French Cooperative Thoracic Intergroup (IFCT): Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. *Lancet*, 2016, 387, s. 1405–1414.
- 32 Baas, P. – Scherpereel, A. – Nowak, A. K., et al.: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. *Lancet*, 2021, 397, s. 375–386.
- 33 Middleton, G. W. – Smith, I. E. – O'Brien, M. E., et al.: Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. *Ann Oncol*, 1998, 9, s. 269–273.
- 34 Muers, M. F. – Stephens, R. J. – Fisher, P., et al.; MS01 Trial Management Group: Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. *Lancet*, 2008, 371, s. 1685–1694.
- 35 Nowak, A. K. – Lesterhuis, W. J. – Kok, P. S., et al.: Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. *Lancet Oncol*, 2020, 21, s. 1213–1223.
- 36 Forde, P. M. – Sun, Z. – Anagnostou, A., et al.: PRE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) – A PRECOG LLC study. *J Clin Oncol*, 2020, 38, s. 9003–9003.
- 37 Nowak, A. K. – Jackson, A. – Sidhu, C.: Management of advanced pleural mesothelioma – at the crossroads. *JCO Oncol Pract*, 2022, 18, s. 116–124.
- 38 Kim, R. Y. – Li, Y. – Marmarelis, M. E., et al.: Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma. *Lung Cancer*, 2021, 159, s. 107–110.
- 39 Fennell, D. A. – Ewings, S. – Ottensmeier, C., et al.; CONFIRM trial investigators: Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. *Lancet Oncol*, 2021, 22, s. 1530–1540.
- 40 Disselhorst, M. J. – Quispel-Janssen, J. – Lalezari, F., et al.: Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. *Lancet Respir Med*, 2019, 7, s. 260–270.
- 41 Scherpereel, A. – Mazieres, J. – Greillier, L., et al.: Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. *J Clin Oncol*, 2017, 35S, ASCO #LBA8507.
- 42 British Thoracic Society Standards of Care Committee: BTS statement on malignant mesothelioma in the UK, 2007. *Thorax*, 2007, 62, suppl. 2, s. ii1–ii19.
- 43 Saunders, J. – Ashton, M. – Hall, C., et al.: Pain management in patients with malignant mesothelioma: challenges and solutions. *Lung Cancer*, 2019, 10, s. 37–46.
- 44 Kindler, H. L. – Ismailia, N. – Armato, S. G. 3rd., et al.: Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*, 2018, 36, s. 1343–1373.
- 45 Rahman, N. M. – Pepperell, J. – Rehal, S., et al.: Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: The TIME1 randomized clinical trial. *JAMA*, 2015, 314, s. 2641–2653.
- 46 Feller-Kopman, D. J. – Reddy, C. B. – DeCamp, M. M., et al.: Management of malignant pleural effusions. An official ATS/STS/STR clinical practice guideline. *Am J Respir Crit Care Med*, 2018, 198, s. 839–849.
- 47 Bhatnagar, R. – Piotrowska, H. E. G. – Laskawiec-Szkonter, M., et al.: Effect of thoracoscopic talc poudrage vs talc slurry via chest tube on pleurodesis failure rate among patients with malignant pleural effusions: a randomized clinical trial. *JAMA*, 2019, 323, s. 60–69.
- 48 Shaw, P. – Agarwal, R.: Pleurodesis for malignant pleural effusions. *Cochrane Database Syst Rev*, 2004, s. CD002916.
- 49 Ukale, V. – Agrenius, V. – Hillerdal, G., et al.: Pleurodesis in recurrent pleural effusions: a randomized comparison of a classical and a currently popular drug. *Lung Cancer*, 2004, 43, s. 323–328.
- 50 Walker-Renard, P. B. – Vaughan, L. M. – Sahn, S. A.: Chemical pleurodesis for malignant pleural effusions. *Ann Intern Med*, 1994, 120, s. 56–64.
- 51 Epelbaum, O. – Rahman, N. M.: Contemporary approach to the patient with malignant pleural effusion complicating lung cancer. *Ann Transl Med*, 2019, 7, s. 352.
- 52 Tremblay, A. – Michaud, G.: Single-center experience with 250 tunneled pleural catheter insertions for malignant pleural effusion. *Chest*, 2006, 129, s. 362–368.
- 53 Bhatnagar, R. – Keenan, E. K. – Morley, A. J., et al.: Outpatient talc administration by indwelling pleural catheter for malignant effusion. *N Engl J Med*, 2018, 378, s. 1313–1322.
- 54 Wahidi, M. M. – Reddy, C. – Yarmus, L., et al.: Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP trial. *Am J Respir Crit Care Med*, 2017, 195, s. 1050–1057.
- 55 Reddy, C. – Ernst, A. – Lamb, C., et al.: Rapid pleurodesis for malignant pleural effusions: a pilot study. *Chest*, 2011, 139, s. 1419–1423.
- 56 Ahmed, L. – Ip, H. – Rao, D., et al.: Talc pleurodesis through indwelling pleural catheters for malignant pleural effusions: retrospective case series of a novel clinical pathway. *Chest*, 2014, 146, s. e190–e194.
- 57 Rusch, V. W., et al.: Malignant pleural mesothelioma. In: Amin, M. B. – Edge, S. B. – Greene, F. L., et al. (eds.): *AJCC Cancer Staging Manual*. New York, Springer, 2017, s. 457–468.

Program časného záchytu karcinomu plic

MUDr. Ivana Čierná Peterová Ordinace Čierná-Peterová, Brandýs nad Labem-Stará Boleslav

- 1 Metodika realizace populačního pilotního programu časného záchytu karcinomu plic. Dostupné z: <https://www.mzcr.cz/metodika-realizace-populacniho-pilotniho-programu-casneho-zachytu-karcinomu-plic/vyhledano> 27. 5. 2022.
- 2 Horeweg, N. – van der Aalst, C. M. – Vliegenthart, R., et al.: Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. *Eur Resp J*, 2013, 42, s. 1659–1667.
- 3 Oudkerk, M. – Devaraj, A. – Vliegenthart, R., et al.: European position statement on lung cancer screening. *Lancet Oncol*, 2017, 18, s. E754–E766, DOI:[https://doi.org/10.1016/S1470-2045\(17\)30861-6](https://doi.org/10.1016/S1470-2045(17)30861-6).
- 4 De Konig, H. – van der Aalst, C. M. – de Jong, P. A., et al.: Reduced lung-cancer mortality with volume CT screening in a randomized trial. *N Engl J Med*, 2020, 382, s. 503–513.
- 5 National Lung Screening Trial Research Team; Aberle, D. R. – Adams, A. M. – Berg, Ch. D., et al.: Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med*, 2011, 365, s. 395–409.
- 6 www.pneumologie.cz
- 7 www.prevenceproplice.cz
- 8 www.copn.cz

Diagnostika a terapie syndromu obstrukční spánkové apnoe

doc. MUDr. Milan Sova, Ph.D. Klinika nemocí plicních a tuberkulózy, FN Brno, Klinika plicních nemocí a tuberkulózy, FN Olomouc

MUDr. Samuel Genzor, Ph.D. | MUDr. Jan Mizera Klinika plicních nemocí a tuberkulózy, FN Olomouc

- 1 Young, T. – Finn, L. – Peppard, P. E., et al.: Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. *Sleep*, 2008, 31, s. 1071–1078.
- 2 Sullivan, C. E. – Issa, F. G., et al.: Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. *Lancet*, 1981, 1, s. 862–865.
- 3 Lopez, P. P. – Stefan, B. – Schulman, C. I., et al.: Prevalence of sleep apnea in morbidly obese patients who presented for weight loss surgery evaluation: more evidence for routine screening for obstructive sleep apnea before weight loss surgery. *Am Surg*, 2008, 74, s. 834–838.
- 4 Kryger, M. – Roth, T. – Dement, W.: *Principles and practice of sleep medicine*. Elsevier, 2015.
- 5 Guilleminault, C. – Partinen, M. – Hollman, K., et al.: Familial aggregates in obstructive sleep apnea syndrome. *Chest*, 1995, 107, s. 1545–1551.
- 6 Redline, S. – Tishler, P. V. – Tosteson, T. D., et al.: The familial aggregation of obstructive sleep apnea. *Am J Respir Crit Care Med*, 1995, 151, s. 682–687.
- 7 Scrima, L. – Broudy, M. – Nay, K. N., et al.: Increased severity of obstructive sleep apnea after bedtime alcohol ingestion: diagnostic potential and proposed mechanism of action. *Sleep*, 1982, 5, s. 318–328.
- 8 Roth, T. – Roehrs, T. – Zorick, F., et al.: Pharmacological effects of sedative-hypnotics, narcotic analgesics, and alcohol during sleep. *Med Clin North Am*, 1985, 69, s. 1281–1288.
- 9 Ding, N. – Lin, W. – Zhang, X. L., et al.: Overnight fluid shifts in subjects with and without obstructive sleep apnea. *J Thorac Dis*, 2014, 6, s. 1736–1741.
- 10 Kales, A. – Cadieux, R. J. – Bixler, E. O., et al.: Severe obstructive sleep apnea: Onset, clinical course, and characteristics. *J Chronic Dis*, 1985, 38, s. 419–425.
- 11 Sonka, K. – Slonkova, J.: Spánková apnoe dospělého věku. *Cesk Slov Neurol N*, 2008, 71, s. 643–656.
- 12 Maislin, G. – Pack, A. I. – Kribbs, N. B., et al.: A survey screen for prediction of apnea. *Sleep*, 1995, 18, s. 158–166.
- 13 Krieger, J. – Laks, L. – Wilcox, I., et al.: Atrial natriuretic peptide release during sleep in patients with obstructive sleep apnoea before and during treatment with nasal continuous positive airway pressure. *Clin Sci*, 1989, 77, s. 407–411.
- 14 Catarino, R. – Spratley, J. – Catarino, I., et al.: Sleepiness and sleep-disordered breathing in truck drivers: risk analysis of road accidents. *Sleep Breath*, 2014, 18, s. 59–68.
- 15 Philip, P. – Sagaspe, P. – Taillard, J., et al.: Maintenance of Wakefulness Test, obstructive sleep apnea syndrome, and driving risk. *Ann Neurol*, 2008, 64, s. 410–416.
- 16 Derderian, S. S. – Bridenbaugh, R. H. – Rajagopal, K. R.: Neurophysiologic symptoms in obstructive sleep apnea improve after treatment with nasal continuous positive airway pressure. *Chest*, 1988, 94, s. 1023–1027.
- 17 Paiva, T. – Farinha, A. – Martins, A., et al.: Chronic headaches and sleep disorders. *Arch Intern Med*, 1997, 157, s. 1701–1705.
- 18 Petersen, M. – Kristensen, E. – Berg, S., et al.: Sexual function in female patients with obstructive sleep apnea. *J Sex Med*, 2011, 8, s. 2560–2568.
- 19 Petersen, M. – Kristensen, E. – Berg, S., et al.: Long-term effects of continuous positive airway pressure treatment on sexuality in female patients with obstructive sleep apnea. *Sex Med*, 2013, 1, s. 62–68.
- 20 Pastore, A. L. – Palleschi, G. – Ripoli, A., et al.: Severe obstructive sleep apnoea syndrome and erectile dysfunction: a prospective randomised study to compare sildenafil vs. nasal continuous positive airway pressure. *Int J Clin Pract*, 2014, 68, s. 995–1000.
- 21 Ashrafian, H. – Toma, T. – Rowland, S. P., et al.: Bariatric surgery or non-surgical weight loss for obstructive sleep apnoea? A systematic review and comparison of meta-analyses. *Obes Surg*, 2015, 25, s. 1239–1250.
- 22 Owens, R. L. – Shafazand, S.: Effects of CPAP and weight loss on OSA outcomes. *J Clin Sleep Med*, 2014, 10, s. 1365–1367.
- 23 Sharples, L. D. – Clutterbuck-James, A. L. – Glover, M. J., et al.: Meta-analysis of randomised controlled trials of oral mandibular advancement devices and continuous positive airway pressure for obstructive sleep apnoea-hypopnoea. *Sleep Med Rev*, 2016, 27, s. 108–124.

První jednorozční data z prospektivní observační studie postcovidových následků u kohorty pacientů z první vlny covidu-19 v Královéhradeckém kraji

MUDr. Mikuláš Skála | MUDr. Michal Kopecký | MUDr. Libor Nevoránek Plicní klinika FN Hradec Králové, Lékařská fakulta Hradec Králové Univerzity Karlovy v Praze

Tereza Junková Lékařská fakulta Hradec Králové Univerzity Karlovy v Praze

doc. MUDr. Vladimír Koblížek, Ph.D. Plicní klinika FN Hradec Králové, Lékařská fakulta Hradec Králové Univerzity Karlovy v Praze

- 1 Dostupné z: <https://www.who.int/health-topics/coronavirus>, vyhledáno 17. 5. 2022.
- 2 Yuki, K. – Fujigoi, M. – Koutsogiannaki, S.: Covid-19 pathophysiology: A review. *Clin Immunol*, 2020, 215, s. 108427.
- 3 Zimmer, C.: The secret life of a coronavirus – an oily, 100-nanometer-wide bubble of genes has killed more than two million people and reshaped the world. Scientists don't quite know what to make of it. Archivováno z originálu dne 28. 12. 2021. Načteno 28. 2. 2021. Dostupné z: <https://www.nytimes.com/2021/02/26/opinion/sunday/coronavirus-alive-dead.html>, vyhledáno 17. 5. 2022
- 4 Dostupné z: <https://covid19.who.int/>, vyhledáno 17. 5. 2022.
- 5 Lamers, M. M. – Haagmans, B. L.: SARS-CoV-2 pathogenesis. *Nat Rev Microbiol*, 2022, 20, s. 270–284.
- 6 Lopez-Leon, S. – Wegman-Ostrosky, T. – Perelman, C., et al.: More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *medRxiv*, 2021, doi: 10.1101/2021.01.27.21250617.
- 7 NICE guideline [NG188], publikováno 18. 12. 2020.

Idiopatická plicní fibróza – farmakologické možnosti léčby

MUDr. Martina Štercllová, Ph.D. Pneumologická klinika 2. LF UK a FN v Motole, Pneumologická klinika 1. LF UK a FTN, Praha

- 1 Selman, M. – Martinez, F. J. – Pardo, A.: Why does an aging smoker's lung develop idiopathic pulmonary fibrosis and not chronic obstructive pulmonary disease? *Am J Respir Crit Care Med*, 2019, 199, s. 279–285.
- 2 Kato, K. – Hecker, L.: NADPH oxidases: Pathophysiology and therapeutic potential in age-associated pulmonary fibrosis. *Redox Biol*, 2020, 33, s. 101541.
- 3 Ghavami, S. – Yeganeh, B. – Zeki, A. A., et al.: Autophagy and the unfolded protein response promote profibrotic effects of TGF- β 1 in human lung fibroblasts. *Am J Physiol Lung Cell Mol Physiol*, 2018, 314, s. L493–L504.
- 4 Parimon, T. – Yao, C. – Stripp, B. R., et al.: Alveolar epithelial type II cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis. *Int J Mol Sci*, 2020, 21, s. 2269.
- 5 Zhou, Y. – Huang, X. – Hecker, L., et al.: Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. *J Clin Invest*, 2013, 123, s. 1096–1108.
- 6 John, A. E. – Graves, R. H. – Pun, K. T., et al.: Translation of pharmacology of an inhaled small molecule $\alpha\beta$ 6 integrin inhibitor for idiopathic pulmonary fibrosis. *Nat Commun*, 2020, 11, s. 4659.
- 7 Suryadevara, V. – Ramchandran, R. – Kamp, D. W., et al.: Lipid mediators regulate pulmonary fibrosis: potential mechanisms and signaling pathways. *Int J Mol Sci*, 2020, 21, s. 4257.
- 8 Duran-Ortiz, S. – List, E. O. – Basu, R., et al.: Extending lifespan by modulating the growth hormone/insulin-like growth factor-1 axis: coming of age. *Pituitary*, 2021, 24, s. 438–456.
- 9 Montero, P. – Milara, J. – Roger, I., et al.: Role of JAK/STAT in interstitial lung diseases; molecular and cellular mechanisms. *Int J Mol Sci*, 2021, 22, s. 6211.
- 10 Hirani, N. – MacKinnon, A. C. – Nicol, L., et al.: Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. *Eur Respir J*, 2021, 57, s. 2002559.
- 11 Jones, M. G. – Andriotis, O. G. – Roberts, J. J., et al.: Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. *Elife*, 2018, 7, s. e36354.
- 12 Vancheri, C.: Common pathways in idiopathic pulmonary fibrosis and cancer. *Eur Respir Rev*, 2013, 22, s. 265–272.
- 13 Brown, K. K. – Flaherty, K. R. – Cottin, V., et al.: Lung function outcomes in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. *Respir Med*, 2019, 146, s. 42–48.
- 14 White, E. S. – Thomas, M. – Stowasser, S., et al.: Challenges for clinical drug development in pulmonary fibrosis. *Front Pharmacol*, 2022, 13, s. 823085.
- 15 Karimi-Shah, B. A. – Chowdhury, B. A.: Forced vital capacity in idiopathic pulmonary fibrosis – FDA review of pirfenidone and nintedanib. *N Engl J Med*, 2015, 372, s. 1189–1191.
- 16 Dostupné z: https://www.clinicaltrials.gov/ct2/results?cond=Idiopathic+Pulmonary+Fibrosis&Search=Apply&recrs=b&recrs=a&recrs=d&age_v=&gndr=&type=&rslt=, vyhledáno 10. 4. 2022.
- 17 Kochan, A. – Ong, S. – Guler, S., et al.: Social media content of

idiopathic pulmonary fibrosis groups and pages on Facebook: cross-sectional analysis. *JMIR Public Health Surveill*, 2021, 7, s. e24199.

18 **Jouneau, S.** – **Crestani, B.** – **Thibault, R.**, et al.: Post hoc analysis of clinical outcomes in placebo- and pirfenidone-treated patients with IPF stratified by BMI and weight loss. *Respiration*, 2022, 101, s. 142–154.

19 **Awano, N.** – **Jo, T.** – **Yasunaga, H.** – **Inomata, M.**, et al.: Body mass

index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis. *ERJ Open Res*, 2021, 7, s. 00037.

20 **Sangani, R. G.** – **Ghio, A. J.** – **Mujahid, H.**, et al.: Outcomes of idiopathic pulmonary fibrosis improve with obesity: a rural appalachian experience. *South Med J*, 2021, 114, s. 424–431.

21 **Ma, Y.** – **Feng, C.** – **Tang, H.**, et al.: Management of BMI is a potential new approach for the prevention of idiopathic pulmonary fibrosis.

Front Genet, 2022, 13, s. 821029.

22 **King, C. S.** – **Flaherty, K. R.** – **Glassberg, M. K.**, et al.: A phase-2 exploratory randomized controlled trial of INO pulse in patients with fibrotic interstitial lung disease requiring oxygen. *Ann Am Thorac Soc*, 2022, 19, s. 594–602.

Očkování pneumologických pacientů proti pneumokokům

doc. MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha

1 **Kolek, V.**: Infekční pneumonie. In: Kolek, V. – Kašák, V., et al.: *Pneumologie*. Maxdorf, Praha, 2014, s. 121–143.

2 **Prymula, R.**: Očkování proti pneumokokovému onemocnění. In: Chlíbek, R., et al.: *Očkování dospělých*. Mladá fronta, Praha, 2019, s. 150–161.

3 **Goncalves, J. M.** – **Martin, N. B.** – **Mendez, L. I.**, et al.: Impact of 13-valent pneumococcal conjugate polysaccharide vaccination in exacerbations rate of COPD patients with moderate to severe obstruction. *Respir Med*, 2018, 137, s. 6–13.

4 **Smetana, J.** – **Chlíbek, R.**: Očkování pacientů s chronickým respiračním onemocněním. In: Chlíbek, R., et al.: *Očkování dospělých*.

Mladá fronta, Praha, 2019, s. 259–266.

5 **Kozáková, J.** – **Okonji, Z.** – **Klímová, M.**, et al.: Invazivní pneumokoková onemocnění v České republice v roce 2019. Zprávy centra epidemiologie a mikrobiologie. SZÚ, Praha, 2020, 29, s. 246–252.

6 **Petroušová, L.** – **Rožnovský, L.**: Pneumokokové infekce u dospělých a jejich prevence. *Med Praxi*, 2013, 10, s. 104–107.

7 **Thomas, R. E.**: Pneumococcal pneumonia and invasive pneumococcal disease in those 65 and older: Rates of detection, risk factors, vaccine effectiveness, hospitalisation and mortality. *Geriatrics*, 2021, 6, s. 1–20.

8 **Jakubec, P.** – **Kolek, V.** – **Kolář, M.**: Diagnostika a léčba těžké

pneumonie. Standard léčebného plánu 2019. Dostupné z: <http://www.pneumologie.cz>.

9 **Torres, A.** – **Cillóniz, C.** – **Blasi, F.**, et al.: Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review. *Respir Med*, 2018, 137, s. 6–13.

10 **Prevenar 13**: Vakcína proti pneumokokovým infekcím. Dostupné z: <https://www.prevenar.cz/>, vyhledáno 6. 6. 2022.

11 **Dušek, L.**: Aktuální data Národního zdravotnického informačního systému. Dostupné z: <https://www.vakcinace.eu/data/files/hradeckevakcinologickedny2019/9.pdf>, vyhledáno 6. 6. 2022.

12 **Chlíbek, R.**, et al.: Očkování dospělých. *Vakcinologie*, 2021, 3.

Vrozené poruchy imunitního systému manifestující se v dospělém věku

MUDr. Zita Chovancová, Ph.D. Ústav klinické imunologie a alergologie FN u sv. Anny v Brně a LF Masarykovy univerzity, Brno

1 **Bousfiha, A.** – **Jeddane, L.** – **Picard, C.**, et al.: Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. *J Clin Immunol*, 2020, 40, s. 66–81.

2 **Tangye, S. G.** – **Al-Herz, W.** – **Bousfiha, A.**, et al.: The Ever-Increasing Array of Novel Inborn Errors of Immunity: an Interim Update by the IUIS Committee. *J Clin Immunol*, 2021, 41, s. 666–679.

3 **Staels, F.** – **Collignon, T.** – **Betrains, A.**, et al.: Monogenic adult-onset inborn errors of immunity. *Front Immunol*, 2021, 12, 753978.

4 **Bousfiha, A. A.** – **Jeddane, L.** – **Ailal, F.**, et al.: Primary immunodeficiency diseases worldwide: more common than generally thought. *J Clin Immunol*, 2013, 33, s. 1–7.

5 **Litzman, J.**: Primární imunodeficiency u dospělých. *Vnitř Lék*, 2019, 65, s. 109–116.

6 **Bjelac, J. A.** – **Yonkof, J. R.** – **Fernandez, J.**: Differing performance of the warning signs for immunodeficiency in the diagnosis of pediatric versus adult patients in a two-center tertiary referral population. *J Clin Immunol*, 2019, 39, s. 90–98.

7 **Mauracher, A. A.** – **Gujer, E.** – **Bachmann, L. M.**, et al.: Patterns of immune dysregulation in primary immunodeficiencies: a systematic review. *J Allergy Clin Immunol Pract*, 2021, 9, s. 792–802.

8 **Rosenberg, E.** – **Dent, P. B.** – **Denburg, J. A.**: Primary immune deficiencies in the adult: a previously underrecognized common condition. *J Allergy Clin Immunol Pract*, 2016, 4, s. 1101–1107.

9 **Srinivasa, B. T.** – **Alizadehfar, R.** – **Desrosiers, M.**, et al.: Adult primary immune deficiency: what are we missing? *Am J Med*, 2012, 125, s. 779–786.

10 **Mansouri, D.** – **Adimi, P.** – **Mirsaedi, M.**, et al.: Primary immune deficiencies presenting in adults: seven years of experience from Iran. *J Clin Immunol*, 2005, 25, s. 385–391.

11 **Anderson, J. T.** – **Cowan, J.** – **Condino-Neto, A.**, et al.: Health-related quality of life in primary immunodeficiencies: Impact of delayed diagnosis and treatment burden. *Clin Immunol*, 2022, 236, 108931.

12 **Slade, C. A.** – **Bosco, J. J.** – **Binh Giang, T.**, et al.: Delayed diagnosis and complications of predominantly antibody deficiencies in a cohort of Australian adults. *Front Immunol*, 2018, 9, s. 694.

13 **Ziętkiewicz, M.** – **Więsik-Szewczyk, E.** – **Matyja-Bednarczyk, A.**, et al.: Shorter diagnostic delay in Polish adult patients with common variable immunodeficiency and symptom onset after 1999. *Front Immunol*, 2020, 11, s. 982.

14 **Soler-Palacin, P.** – **de Gracia, J.** – **González-Granado, L. I.**, et al.: Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management. *Respir Res*, 2018, 19, s. 219.

15 **Grammatikos, A.** – **Bright, P.** – **Bhatnagar, R.**, et al.: How to investigate a suspected immune deficiency in adults. *Respir Med*, 2020, 171, 106100.

16 **Azar, A. E.** – **Ballas, Z. K.**: Evaluation of the adult with suspected immunodeficiency. *Am J Med*, 2007, 120, s. 764–768.

17 **Yazdani, R.** – **Habibi, S.** – **Sharif, L.**, et al.: Common variable immunodeficiency: epidemiology, pathogenesis, clinical manifestations, diagnosis, classification, and management. *J Invest Allergol Clin Immunol*, 2020, 30, s. 14–34.

18 **Guevara-Hoyer, K.** – **Fuentes-Antrás, J.** – **Calatayud Gastardi, J.**, et al.: Immunodeficiency and thymoma in Good syndrome: Two sides of the same coin. *Immunol Lett*, 2021, 231, s. 11–17.

19 **Yazdani, R.** – **Azizi, G.** – **Abolhassani, H.**, et al.: Selective IgA deficiency: epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management. *Scand J Immunol*, 2017, 85, s. 3–12.

20 **Odnoletkova, I.** – **Kindle, G.** – **Quinti, I.**, et al.: The burden of common

variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data. *Orphanet J Rare Dis*, 2018, 13, s. 201.

21 **Bonilla, F. A.** – **Barlan, I.** – **Chapel, H.**, et al.: International Consensus Document (ICON): Common variable immunodeficiency disorders. *J Allergy Clin Immunol Pract*, 2016, 4, s. 38–59.

22 **Hanitsch, L. G.** – **Wittke, K.** – **Stittrich, A. B.**, et al.: Interstitial lung disease frequently precedes CVID diagnosis. *J Clin Immunol*, 2019, 39, s. 849–851.

23 **Lopes, J. P.** – **Ho, H. E.** – **Cunningham-Rundles, C.**: Interstitial lung disease in common variable immunodeficiency. *Front Immunol*, 2021, 12, 605945.

24 **Sharma, S.** – **Pilania, R. K.** – **Anjani, G.**, et al.: Lymphoproliferation in inborn errors of immunity: the eye does not see what the mind does not know. *Front Immunol*, 2022, 13, 856601.

25 **Resnick, E. S.** – **Moshier, E. L.** – **Godbold, J. H.**, et al.: Morbidity and mortality in common variable immune deficiency over 4 decades. *Blood*, 2012, 119, s. 1650–1657.

26 **Uzzan, M.** – **Ko, H. M.** – **Mehandru, S.**, et al.: Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD). *Curr Gastroenterol Rep*, 2016, 18, s. 17.

27 **Malamut, G.** – **Verkarre, V.** – **Suarez, F.**, et al.: The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. *Am J Gastroenterol*, 2010, 105, s. 2262–2275.

28 **Shi, Y.** – **Wang, C.**: When the Good syndrome goes bad: a systematic literature review. *Front Immunol*, 2021, 12, 679556.

Dlouhodobá léčba astmatu

doc. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie 3. LF UK a Fakultní nemocnice Bulovka, vedoucí Národního centra pro těžkou astma Fakultní nemocnice Bulovka, Praha

1 GINA (Global Initiative for Asthma): *Global Strategy for Asthma Management and Prevention*. 2022, dostupné z: <http://www.ginasthma.org>.

2 **Teřl, M.** – **Čáp, P.** – **Dvořáková, R.**, et al.: *Doporučený postup diagnostiky a léčby bronchiálního astmatu 2019*. Dostupné z:

www.pneumologie.cz.

3 **Kašák, V.**: www.mujihalator.cz.

Relvar Ellipta u pacienta s rozsáhlou medikací – kazuistika

MUDr. Petra Adámková | doc. MUDr. Jaromír Bystron, CSc. Oddělení alergologie a klinické imunologie FN Ostrava a LF Ostravské univerzity, Ostrava

1 Dostupné z: https://ginasthma.org/wp-content/uploads/2020/04/Main-pocket-guide_2020_04_03-final-wms.pdf, vyhledáno 7. 12. 2021.

2 **Kašák, V.**: Fluticason furoát/vilanterol trifénatát – nová fixní

kombinace v léčbě astmatu a chronické obstrukční plicní nemoci. *Remedia*, 2015, 25, s. 1–4.

3 **Kašák, V.**: Nové léky pro léčbu astmatu a CHOPN na našem farmaceutickém trhu. *Alergie*, 2015, 17, s. 183–190.

4 **Kašák, V.**: Flutikason furoát/vilanterol trifénatát – nová fixní kombinace v léčbě chronické obstrukční plicní nemoci. *Farmakoterapie*, 2015, 11, s. 410–414.

5 SPC Relvar Ellipta.

Biologická léčba těžkého astmatu – současné možnosti a výhledy

MUDr. Beáta Hutytová, Ph.D. Oddělení alergologie a klinické imunologie, FN Olomouc, Ústav imunologie, LF UP, Olomouc

- Global Strategy for Asthma Management and Prevention (2021 Update). Dostupné z: <https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf>, vyhledáno 30. 4. 2022.
- Kašák, V.: *Asthma bronchiale*. Maxdorf, Praha, 2013.
- Teřl, M. – Čáp, P. – Dvořáková, R., et al.: *Doporučený postup diagnostiky a léčby bronchiálního astmatu*. GEUM, Semily, 2015.
- Stokes, J. R. – Casale, T. B.: Characterization of asthma endotypes: implications for therapy. *Ann Allergy Asthma Immunol*, 2016, 117, s. 121–125.
- Novosad, J. – Krčmová, I.: Biologická léčba eozinofilních fenotypů těžkého bronchiálního astmatu. *Stud Pneumol Phthiseol*, 2018, 78, s. 122–133.
- Brusselle, G. G. – Koppelman, G. H.: Biologic therapies for severe asthma. *N Engl J Med*, 2022, 386, s. 157–171.
- Sze, E. – Bhalla, A. – Nair, P.: Mechanisms and therapeutic strategies for non-T2 asthma. *Allergy*, 2020, 75, s. 311–325.
- Chung, K. F. – Wenzel, S. E. – Brozek, J. L., et al.: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*, 2014, 43, s. 343–373.
- Státní ústav pro kontrolu léčiv. Dostupné z: <http://www.sukl.cz/modules/medication>, vyhledáno 30. 4. 2022.
- Krings, J. G. – McGregor, M. C. – Bacharier, L. B., et al.: Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent. *J Allergy Clin Immunol Pract*, 2019, 7, s. 1379–1392.
- Mitchell, P. D. – El-Gamhal, A. I. – O'Byrne, P. M.: Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma. *Clin Pharmacol Ther*, 2016, 99, s. 38–48.
- Pavord, I. D. – Korn, S. – Howarth, P., et al.: Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. *Lancet*, 2012, 380, s. 651–659.
- Castro, M. – Malthur, S. – Hargreave, F., et al.: Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. *Am J Respir Crit Care Med*, 2011, 184, s. 1125–1132.
- Castro, M. – Wenzel, S. E. – Bleeker, E. R., et al.: Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. *Lancet Respir Med*, 2014, 2, s. 879–890.
- Bleeker, E. R. – FitzGerald, J. M. – Chanez, P., et al.: Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dose inhaled corticosteroids and long-acting β_2 -agonists (SI-ROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet*, 2016, 388, s. 2115–2127.
- FitzGerald, J. M. – Bleeker, E. R. – Nair, P., et al.: Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*, 2016, 388, s. 2128–2141.
- Nair, P. – Wenzel, S. E. – Rabe, K. F., et al.: Oral glucocorticoid-sparing effect of benralizumab in severe asthma. *N Engl J Med*, 2017, 376, s. 2448–2458.
- Gandhi, N. A. – Bennett, B. L. – Graham, N. H. M., et al.: Targeting key proximal drivers of type 2 inflammation in disease. *Nat Rev Drug Discov*, 2016, 15, s. 35–50.
- Cevhertars, L. – Ogulur, I. – Maurer, D. J., et al.: Advances and recent developments in asthma in 2020. *Allergy*, 2020, 75, s. 3124–3146.
- Sugita, K. – Steer, C. A. – Martinez-Gonzalez, I., et al.: Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. *J Allergy Clin Immunol*, 2018, 141, s. 300–310.
- Busse, W. W. – Kraft, M. – Rabe, K. F., et al.: Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. *Eur Respir J*, 2021, 58, 2003393.
- Wenzel, S. – Ford, L. – Pearlman, D., et al.: Dupilumab in persistent asthma with elevated eosinophil levels. *N Engl J Med*, 2013, 368, s. 2455–2466.
- Wenzel, S. – Castro, M. – Corren, J., et al.: Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β_2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet*, 2016, 388, s. 31–44.
- Nettis, E. – Patella, V. – Lombardo, C., et al.: Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis. *Allergy*, 2020, 75, s. 2653–2661.
- El-Naccache, D. W. – Haskó, G. – Gause, W. C.: Early events triggering the initiation of a type 2 immune response. *Trends Immunol*, 2021, 42, s. 151–164.
- Menzies-Gow, A. – Corren, J. – Bourdin, A., et al.: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. *N Engl J Med*, 2021, 384, s. 1800–1809.
- Wechsler, M. E. – Ruddy, M. K. – Pavord, I. D., et al.: Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. *N Engl J Med*, 2021, 385, s. 1656–1668.
- Kelsen, S. G. – Agache, I. O. – Soong, W., et al.: Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. *J Allergy Clin Immunol*, 2021, 148, s. 790–798.

Klinická účinnost kombinace budesonidu a formoterol fumarátu (Easyhaler) u nemocných se špatně kontrolovanou obstrukční nemocí dýchacích cest

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- Tamási, L. – Szilasi, M. – Gálffy, G.: Clinical effectiveness of budesonide/formoterol fumarate Easyhaler for patients with poorly controlled obstructive airway disease: a real-world study of patient-reported outcomes. *Adv Ther*, 2018, 35, s. 1140–1152.

Fixní trojkombinace IKS/LAMA/LABA v inhalačním systému NEXThaler

MUDr. Samuel Genzor, Ph.D. Klinika plicních nemocí a tuberkulózy FN a LF Univerzity Palackého, Olomouc

- Kertsjens, H. A. M. – Engel, M. – Dahl, R., et al.: Tiotropium in asthma poorly controlled with standard combination therapy. *N Engl J Med*, 2012, s. 1198–1207.
- Kertsjens, H. A. M. – Casale, T. B. – Bleeker, E. R., et al.: Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind placebo-controlled, parallel-group, active-comparator, randomised trials. *Lancet Respir Med*, 2015, s. 367–376.
- Kew, K. M. – Dahri, K.: Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta-2-agonists and inhaled corticosteroids (LABA/IKS) versus LABA/ICS for adults with asthma. *Cochrane Database Syst Rev*, 2016, CD011721.
- Walker, F. B. – Kaiser, D. L. – Kowal, M. B., et al.: Prolonged effect of inhaled glycopyrrolate in asthma. *Chest*, 1987, 91, s. 49–51.
- Virchow, J. C. – Kuna, P. – Paggiaro, P., et al.: Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. *Lancet*, 2019, 394, s. 1737–1749.
- Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Dostupné z: <https://goldcopd.org>, vyhledáno 14. 5. 2022.
- Papí, A. – Vestbo, J. – Fabbri, L. M., et al.: Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (tribute): a double-blind, parallel group, randomised controlled trial. *Lancet*, 2018, 391, s. 1076–1084.
- Singh, D. – Fabbri, K. M. – Corradi, M., et al.: Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. *Eur Respir J*, 2019, 1, 53, 1900235.
- Zheng, J. – Baldi, S. – Zhao, L., et al.: Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSITY randomised controlled trial. *Respir Res*, 2021, 22, s. 90.
- Marth, K. – Renner, A. – Pohl, W.: TRICOP – A real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD. *Respir Med*, 2021, 182, s. 106398.
- Usmani, O. S.: Choosing the right inhaler for your asthma or COPD patient. *Ther Clin Risk Manag*, 2019, 15, s. 461–472.
- Lavoroni, F. – Corrigan, C. J. – Barnes, P. J., et al.: Aerosol Drug Management Improvement Team. Retail sales of inhalation devices in European countries: so much for a global policy. *Respir Res*, 2011, 105, s. 1099–1103.
- Ghosh, S. – Ohar, J. A. – Bradley Drummond, M.: Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. *J Aerosol Med Pulm Drug Deliv*, 2017, 30, s. 381–387.
- Buttini, F. – Brambilla, G. – Copelli, D., et al.: Effect of flow rate on in vitro aerodynamic performance of NEXThaler in comparison with Discus and Turbohaler dry powder inhalers. *J Aerosol Med Pulm Drug Deliv*, 2016, 29, s. 167–178.
- Virchow, J. C. – Poli, G. – Herpich, C., et al.: Lung deposition of the dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate using NEXThaler device in healthy subjects, asthmatic patients, and COPD patients. *J Aerosol Med Pulm Drug Deliv*, 2018, 31, s. 269–280.
- Usmani, O. S.: Treating the small airways. *Respiration*, 2012, 84, s. 441–453.
- Sonnappa, S. – McQueen, B. – Postma, D. S., et al.: Extrafine versus fine inhaled corticosteroids in relation to asthma control: a systematic review and meta-analysis of observational real-life studies. *J Allergy Clin Immunol Pract*, 2018, 6, s. 907.e7–915.e7.
- Sonnappa, S. – Martin, R. – Israel, E., et al.: Respiratory Effectiveness Group, Small Airways Study Group. Risk of pneumonia in obstructive lung disease: a real-life study comparing extra-fine and fine-particle inhaled corticosteroids. *PLoS One*, 2017, 12, e0178112.
- Beeh, K. M. – Kuna, P. – Corradi, M., et al.: Comparison of dry-powder inhaler and pressurized metered-dose inhaler formulations of extrafine beclomethasone dipropionate/formoterol fumarate/glycopyrronium in patients with COPD: The TRI-D randomized controlled trial. *Int J Chron Obstruct Pulmon Dis*, 2021, 16, s. 79–89.

Problematika indikace augmentační léčby deficitu α_1 -antitrypsinu

MUDr. Jan Chlumský, Ph.D. | MUDr. Eva Bartošovská Národní centrum pro deficit α_1 -antitrypsinu, Pneumologická klinika, 1. LF UK a Fakultní Thomayerova nemocnice, Praha

- Miravittles, M. – Dirksen, A. – Ferrarotti, I., et al.: European Respiratory Society statement: Diagnosis and treatment of pulmonary disease in α_1 -antitrypsin deficiency. *Eur Respir J*, 2017, 50.
- de Serres, F. J. – Blanco, I. – Fernández-Bustillo, E.: Pi S and Pi Z alpha-1 antitrypsin deficiency worldwide. A review of existing genetic epidemiological data. *Monaldi Arch Chest Dis*, 2007, 67, s. 184–208.
- McElvaney, G. N. – Sandhaus, R. A. – Miravittles, M., et al.: Clinical considerations in individuals with α_1 -antitrypsin Pi*SZ genotype. *Eur Respir J*, 2020, 55, s. 1902410.
- Franciosi, A. N. – Fraughen, D. – Carroll, T. P., et al.: Alpha-1 antitrypsin deficiency: clarifying the role of the putative protective threshold. *Eur Respir J*, 2022, 59, s. 2101410.
- McElvaney, N. G. – Burdon, J. – Holmes, M., et al.: Long-term efficacy and safety of a1 proteinase inhibitor treatment for emphysema caused by severe a1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). *Lancet Respir Med*, 2017, 5, s. 51–60.
- Chlumský, J.: Standard pro diagnostiku a léčbu pacientů s CHOPN s prokázanou deficiencí alfa-1 antitrypsinu. In: Kolek, V. (ed.): *Doporučené postupy v pneumologii*. Maxdorf, Praha, 2019.